Clinical Trials
26 trialsNCT04997902 2026-06-05
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Phase 1/2 Completed
NCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07628062 2026-06-04
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT01451853 2026-06-03
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
Phase 2 Withdrawn
NCT04881045 2026-06-02
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
Phase 1 Completed
NCT05787587 2026-06-02
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Active not recruiting
NCT06525220 2026-06-02
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Phase 3 Recruiting
NCT06788990 2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3 Recruiting
NCT04590963 2026-06-01
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT06003231 2026-06-01
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT07613723 2026-05-29
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Zelluna Immunotherapy AS
Phase 1 Recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06657222 2026-05-27
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Phase 1/2 Recruiting
NCT06256588 2026-05-26
JADE
GlaxoSmithKline
Phase 3 Recruiting
NCT04534205 2026-05-22
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT04541108 2026-05-22
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Active not recruiting
NCT06062420 2026-05-22
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
Phase 2 Active not recruiting
NCT07601204 2026-05-22
Treatment of Recurrent/Metastatic Head and Neck Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT06172478 2026-05-15
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 2 Recruiting